XML 71 R30.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of significant expenses of the CODM function The CODM function is regularly provided with the following significant segment expenses:
Year Ended December 31,
 202520242023
Oncology clinical trial related costs$266,439 $100,937 $35,224 
Acquired in-process research and development— 15,007 520,915 
Compensation related costs, excluding stock-based compensation75,575 48,295 31,371 
Stock-based compensation732,420 50,981 14,108 
Other expenses (1)
19,990 10,778 8,032 
Total segment expenses
1,094,424 225,998 609,650 
Other income, net14,838 13,369 11,183 
Interest expense— (8,686)(16,461)
Net loss$(1,079,586)$(221,315)$(614,928)

(1) Other expenses include general and administrative expenses excluding compensation and stock-based compensation.